Sett R, Basu N, Ghosh A K, Das P K
Leishmania Group, Indian Institute of Chemical Biology, Calcutta.
J Parasitol. 1992 Apr;78(2):350-4.
Doxorubicin, a well characterized anticancer drug, was tested in vitro and in vivo for activity against Leishmania donovani. Activity in vitro was very high against both the promastigote and amastigote forms of this parasite with 50% effective dose (ED50) values on the order of 0.43 microM and 0.86 microM, respectively. An in vivo inhibition of spleen parasite burden up to 95% in an infected mouse model was achieved when a dosage of 625 micrograms doxorubicin/kg body weight/day was given in 4 consecutive doses, which is far less than the toxic dose. These results suggest that doxorubicin is highly active against visceral leishmaniasis and may be considered with second-line therapeutic agents such as amphotericin B and pentamidine.
阿霉素是一种特性明确的抗癌药物，在体外和体内对杜氏利什曼原虫进行了抗活性测试。其体外活性对该寄生虫的前鞭毛体和无鞭毛体形式都非常高，50%有效剂量（ED50）值分别约为0.43微摩尔和0.86微摩尔。在感染小鼠模型中，当以625微克阿霉素/千克体重/天的剂量连续给药4次时，脾脏寄生虫负荷的体内抑制率高达95%，这远低于毒性剂量。这些结果表明阿霉素对内脏利什曼病具有高度活性，可与二线治疗药物如两性霉素B和喷他脒一起考虑使用。
